AI assistant
Emergent BioSolutions Inc. — Annual Report 2025
Mar 20, 2026
32870_10-k_2026-03-20_b4343614-74c4-43ff-af3b-edb4d57de674.zip
Annual Report
Open in viewerOpens in your device viewer
ARS 1 ebsi_2025annualreport.htm ARS Document generated by Workiva Inc ebsi_2025annualreport
ebsi_2025annualreport001.jpg
Annual Report Preparedness today, safer tomorrow 20 25
ebsi_2025annualreport002.jpg
Dear Fellow Shareholders, In 2025, we made meaningful progress toward our multi-year strategy to turnaround and transform Emergent. As we continue our transformation journey, we remain committed to our mission to protect and save lives, while prioritizing patient safety, quality and compliance and advancing the operational and strategic priorities essential to long-term growth. This year we took important steps to strengthen our financial position through a customer- focused, lean and efficient business model, strong operating results, margin improvements and significant debt repayment. These actions, combined with the strategic divestitures and operational initiatives executed in 2024, enhanced our balance sheet and reinforced the foundation needed to support sustainable value creation. We successfully achieved several important milestones, including: Looking ahead, we are focused on the transformation of our company by investing in revenue growth drivers across both the MCM and naloxone businesses by advancing our internal pipeline, expanding our international revenue and pursuing targeted acquisitions and external opportunities that leverage our infrastructure and scale. Our products help protect communities and address critical public health challenges like smallpox, anthrax, botulism, Ebola and opioid overdoses. I want to express my deepest gratitude to my incredible colleagues at Emergent for another strong year of achievements and advancements. We believe Emergent is well positioned to deliver a strong 2026 and beyond. We are confident in our ability to transform the company and fulfill our mission to protect and save lives. Joe Papa President and CEO Delivered strong earnings and cash flow, improved our cash balance by $100M and reduced our debt by $110M. Secured multiple U.S. government contract awards for biodefense preparedness and delivered medical countermeasures to over 20 countries. Distributed over 100 million doses of NARCAN® Nasal Spray across the U.S. and Canada since 2016. Expanded naloxone portfolio by acquiring exclusive commercial rights to KLOXXADO® (naloxone HCI) Nasal Spray 8 mg and maintained market leadership position for NARCAN® Nasal Spray 4 mg. Divested Baltimore-Bayview facility for $36.5M while retaining rights to secure manufacturing capacity for future growth. Received U.S. FDA approval for drug product manufacturing of raxibacumab at Winnipeg facility. Announced investment agreement with Swiss Rockets AG and pursued strategic collaboration with its subsidiary Rocketvax. Advanced key initiatives to enhance quality and operational excellence across the enterprise.
ebsi_2025annualreport003.jpg
ebsi_2025annualreport004.jpg
ebsi_2025annualreport005.jpg
ebsi_2025annualreport006.jpg
ebsi_2025annualreport007.jpg
ebsi_2025annualreport008.jpg
ebsi_2025annualreport009.jpg
ebsi_2025annualreport010.jpg
ebsi_2025annualreport011.jpg
ebsi_2025annualreport012.jpg
ebsi_2025annualreport013.jpg
ebsi_2025annualreport014.jpg
ebsi_2025annualreport015.jpg
ebsi_2025annualreport016.jpg
ebsi_2025annualreport017.jpg
ebsi_2025annualreport018.jpg
ebsi_2025annualreport019.jpg
ebsi_2025annualreport020.jpg
ebsi_2025annualreport021.jpg
ebsi_2025annualreport022.jpg
ebsi_2025annualreport023.jpg
ebsi_2025annualreport024.jpg
ebsi_2025annualreport025.jpg
ebsi_2025annualreport026.jpg
ebsi_2025annualreport027.jpg
ebsi_2025annualreport028.jpg
ebsi_2025annualreport029.jpg
ebsi_2025annualreport030.jpg
ebsi_2025annualreport031.jpg
ebsi_2025annualreport032.jpg
ebsi_2025annualreport033.jpg
ebsi_2025annualreport034.jpg
ebsi_2025annualreport035.jpg
ebsi_2025annualreport036.jpg
ebsi_2025annualreport037.jpg
ebsi_2025annualreport038.jpg
ebsi_2025annualreport039.jpg
ebsi_2025annualreport040.jpg
ebsi_2025annualreport041.jpg
ebsi_2025annualreport042.jpg
ebsi_2025annualreport043.jpg
ebsi_2025annualreport044.jpg
ebsi_2025annualreport045.jpg
ebsi_2025annualreport046.jpg
ebsi_2025annualreport047.jpg
ebsi_2025annualreport048.jpg
ebsi_2025annualreport049.jpg
ebsi_2025annualreport050.jpg
ebsi_2025annualreport051.jpg
ebsi_2025annualreport052.jpg
ebsi_2025annualreport053.jpg
ebsi_2025annualreport054.jpg
ebsi_2025annualreport055.jpg
ebsi_2025annualreport056.jpg
ebsi_2025annualreport057.jpg
ebsi_2025annualreport058.jpg
ebsi_2025annualreport059.jpg
ebsi_2025annualreport060.jpg
ebsi_2025annualreport061.jpg
ebsi_2025annualreport062.jpg
ebsi_2025annualreport063.jpg
ebsi_2025annualreport064.jpg
ebsi_2025annualreport065.jpg
ebsi_2025annualreport066.jpg
ebsi_2025annualreport067.jpg
ebsi_2025annualreport068.jpg
ebsi_2025annualreport069.jpg
ebsi_2025annualreport070.jpg
ebsi_2025annualreport071.jpg
ebsi_2025annualreport072.jpg
ebsi_2025annualreport073.jpg
ebsi_2025annualreport074.jpg
ebsi_2025annualreport075.jpg
ebsi_2025annualreport076.jpg
ebsi_2025annualreport077.jpg
ebsi_2025annualreport078.jpg
ebsi_2025annualreport079.jpg
ebsi_2025annualreport080.jpg
ebsi_2025annualreport081.jpg
ebsi_2025annualreport082.jpg
ebsi_2025annualreport083.jpg
ebsi_2025annualreport084.jpg
ebsi_2025annualreport085.jpg
ebsi_2025annualreport086.jpg
ebsi_2025annualreport087.jpg
ebsi_2025annualreport088.jpg
ebsi_2025annualreport089.jpg
ebsi_2025annualreport090.jpg
ebsi_2025annualreport091.jpg
ebsi_2025annualreport092.jpg
ebsi_2025annualreport093.jpg
ebsi_2025annualreport094.jpg
ebsi_2025annualreport095.jpg
ebsi_2025annualreport096.jpg
ebsi_2025annualreport097.jpg
ebsi_2025annualreport098.jpg
ebsi_2025annualreport099.jpg
ebsi_2025annualreport100.jpg
ebsi_2025annualreport101.jpg
ebsi_2025annualreport102.jpg
ebsi_2025annualreport103.jpg
ebsi_2025annualreport104.jpg
ebsi_2025annualreport105.jpg
ebsi_2025annualreport106.jpg
ebsi_2025annualreport107.jpg
ebsi_2025annualreport108.jpg
ebsi_2025annualreport109.jpg
ebsi_2025annualreport110.jpg
ebsi_2025annualreport111.jpg
ebsi_2025annualreport112.jpg
ebsi_2025annualreport113.jpg
ebsi_2025annualreport114.jpg
ebsi_2025annualreport115.jpg
ebsi_2025annualreport116.jpg
ebsi_2025annualreport117.jpg
ebsi_2025annualreport118.jpg
ebsi_2025annualreport119.jpg
ebsi_2025annualreport120.jpg
ebsi_2025annualreport121.jpg
ebsi_2025annualreport122.jpg
ebsi_2025annualreport123.jpg
ebsi_2025annualreport124.jpg
ebsi_2025annualreport125.jpg
ebsi_2025annualreport126.jpg
ebsi_2025annualreport127.jpg
ebsi_2025annualreport128.jpg
ebsi_2025annualreport129.jpg
ebsi_2025annualreport130.jpg
ebsi_2025annualreport131.jpg
ebsi_2025annualreport132.jpg
ebsi_2025annualreport133.jpg
ebsi_2025annualreport134.jpg
ebsi_2025annualreport135.jpg
ebsi_2025annualreport136.jpg
ebsi_2025annualreport137.jpg
ebsi_2025annualreport138.jpg
ebsi_2025annualreport139.jpg
ebsi_2025annualreport140.jpg
ebsi_2025annualreport141.jpg
ebsi_2025annualreport142.jpg
ebsi_2025annualreport143.jpg
ebsi_2025annualreport144.jpg
ebsi_2025annualreport145.jpg
ebsi_2025annualreport146.jpg
ebsi_2025annualreport147.jpg
EXECUTIVE OFFICERS BOARD OF DIRECTORS CORPORATE HEADQUARTERS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM INVESTOR RELATIONS STOCK TRANSFER AGENT AND REGISTRAR ANNUAL MEETING MARKET INFORMATION CORPORATE GOVERNANCE Investors with questions concerning account information, new certificate issuances, lost or stolen certificate replacement, securities transfers, or the processing of a change of address should contact: . Our chief executive officer intends to submit his annual chief executive officer certification to the New York Stock Exchange within 30 days of the date of our Annual Meeting of Stockholders in accordance with the New York Stock Exchange listing requirements. Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. Our Board of Directors has adopted Corporate Governance Guidelines, along with the charters of the Board Committees and a Code of Conduct and Business Ethics for directors, officers and employees, all of which are available on the company’s website at www.emergentbiosolutions.com. Additional copies of the company’s Form 10-K for the year ended December 31, 2025 of the exhibits thereto, are available without charge upon written request to Investor Relations, Emergent BioSolutions Inc., 300 Professional Drive, Gaithersburg, MD 20879 or by accessing the company's website at www.emergentbiosolutions.com. Broadridge Corporate Issuer Solutions, Inc. *All titles are as of 3/10/2026 Joseph Papa President, CEO and Director Richard Lindahl Executive Vice President, Chief Financial Officer Coleen Glessner Executive Vice President, Quality and Ethics and Compliance Jessica Perl Senior Vice President, General Counsel and Corporate Secretary William Hartzel Senior Vice President, Manufacturing and Bioservices Paul Williams Senior Vice President, Head of Products Business Simon Lowry Senior Vice President, Chief Medical Officer, Head of Research and Development Stephanie Duatschek Chief Global Strategy and Franchise Development Officer Michelle Pepin Senior Vice President and Chief Human Resources Officer Zsolt Harsanyi, Ph.D. Independent Director, Chairman of the Board Former Chief Executive Officer and Chairman of the Board, Exponential Biotherapies Inc. Audit and Finance Committee Member Quality, Compliance, Manufacturing and Risk Management Committee Member Scientific Review Committee Member Neal Fowler Independent Director Chief Executive Officer of Pathalys Pharma, Inc. Audit and Finance Committee Member Scientific Review Committee Member Sujata Dayal Independent Director Former Vice President and Global Chief Compliance Officer, Medline Industries, Inc. Chair, Quality, Compliance, Manufacturing and Risk Management Committee Audit and Finance Committee Member Keith Katkin Independent Director Former Chief Executive Officer, Urovant Sciences Ltd. Compensation Committee Member Nominating and Corporate Governance Committee Member Marvin White Independent Director President and Chief Executive Officer, Aptevo Therapeutics Inc. Chair, Audit and Finance Committee Scientific Review Committee Member Donald DeGolyer Independent Director Founder and Former Chief Executive Officer and Director of Vertice Pharma (a Warburg Pincus company) Chair, Compensation Committee Quality, Compliance, Manufacturing and Risk Management Committee Member Ronald Richard Independent Director Former President and Chief Executive Officer, The Cleveland Foundation Chair, Nominating and Corporate Governance Committee Compensation Committee Member Kathryn Zoon, Ph.D. Independent Director Scientist Emeritus, National Institute of Allergy and Infectious Diseases at the National Institutes of Health Chair, Scientific Review Committee Nominating and Corporate Governance Committee Member Quality, Compliance, Manufacturing and Risk Management Committee Member 300 Professional Drive Gaithersburg, MD 20879 Tel: 240-631-3200 Fax: 240-631-3203 Ernst & Young LLP, McLean, VA, United States P.O. Box 1342 Brentwood, NY 11717 1-877-830-4936 or 1-720-378-5591 [email protected] Richard Lindahl Executive Vice President, Chief Financial Officer (240) 631-3360 [email protected] Emergent BioSolutions Inc.’s common stock trades on the New York Stock Exchange under the trading symbol "EBS." The annual meeting of Emergent BioSolutions Inc. will be held in virtual format via live audio webcast on April 29, 2026 at 9:00 a.m. Eastern Time. Stockholders can attend the meeting online at www.virtualshareholdermeeting.com/EBS2026 John Fowler, Jr. Independent Director Chair, Board of Trustees of the University of Virginia Darden School Foundation; Former Vice Chairman, Corporate and Investment Banking, Wells Fargo Audit and Finance Committee Member
ebsi_2025annualreport148.jpg
300 Professional Drive Gaithersburg, Maryland emergentbiosolutions.com